Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
NCT06295770Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in fibrillary glomerulonephritis (FGN), sponsored by Mayo Clinic. Started Jun 2024; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
fibrillary glomerulonephritis (FGN)
Beyond the preview
Go deeper on NCT06295770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295770.